Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma

[1]  T. Choueiri,et al.  Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. , 2014, Clinical genitourinary cancer.

[2]  R. Figlin,et al.  Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma , 2014, British Journal of Cancer.

[3]  N. Vogelzang,et al.  A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis. , 2013, Clinical genitourinary cancer.

[4]  J. Droz,et al.  Sorafenib and sunitinib for elderly patients with renal cell carcinoma. , 2013, Journal of geriatric oncology.

[5]  R. Figlin,et al.  Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma. , 2013, Journal of geriatric oncology.

[6]  V. Zagonel,et al.  Safety and activity of sunitinib in elderly patients (≥ 70 years) with metastatic renal cell carcinoma: a multicenter study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  S. Oudard,et al.  Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. , 2012, Cancer treatment reviews.

[8]  R. Figlin,et al.  Novel agents and approaches for advanced renal cell carcinoma. , 2012, The Journal of urology.

[9]  Y. Kawano,et al.  Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan , 2012, International journal of urology : official journal of the Japanese Urological Association.

[10]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[11]  R. Figlin,et al.  Systemic Therapies for Metastatic Renal Cell Carcinoma in Older Adults , 2011, Drugs & aging.

[12]  M. Extermann.  Basic Assessment of the Older Cancer Patient , 2011, Current treatment options in oncology.

[13]  L. Klotz,et al.  Age‐related properties of the tumour vasculature in renal cell carcinoma , 2011, BJU international.

[14]  J. Bellmunt,et al.  Experience with sorafenib and the elderly patient , 2010, Medical oncology.

[15]  Hermann Brenner,et al.  Clinical relevance of conditional survival of cancer patients in europe: age-specific analyses of 13 cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Kelly,et al.  Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor , 2009, Targeted Oncology.

[18]  R. Barr,et al.  Psychosocial issues and quality of life. , 2009, Seminars in oncology.

[19]  J. Bellmunt,et al.  The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations , 2009, BJU international.

[20]  P. O'Connor,et al.  Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 , 2008, Clinical Cancer Research.

[21]  B. Guillonneau,et al.  Renal cell carcinoma in young and old patients--is there a difference? , 2008, The Journal of urology.

[22]  F. Guillé,et al.  Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. , 2007, European urology.

[23]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[24]  J E Ware,et al.  Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. , 1998, Journal of clinical epidemiology.

[25]  S. Fukuhara,et al.  Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. , 1998, Journal of clinical epidemiology.

[26]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.